Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14551 - 14575 of 15275 in total
Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia).
Investigational
Matched Description: … Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and
Suplatast is under investigation in clinical trial NCT05983471 (Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)).
Investigational
Matched Description: … Suplatast is under investigation in clinical trial NCT05983471 (Efficacy and Safety of ME-015 (Suplatast …
AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.
Investigational
Matched Description: … It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. …
TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder). TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine.
Investigational
Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
Investigational
Matched Description: … It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic …
Experimental
Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Investigational
Matched Description: … Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and
Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .
Experimental
Matched Description: … It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388]. …
Dipropyl-4-hydroxytryptamine is the 4-hydroxyl analog of dipropyltryptamine (DPT). Dipropyl-4-hydroxytryptamine was first synthesized by Alexander Shulgin. This agent and its properties haven't been fully elucidated.
Experimental
Matched Description: … This agent and its properties haven't been fully elucidated. …
Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced C-met-positive Non-small Cell Lung Cancer).
Investigational
Matched Description: … Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety …
LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).
Investigational
Matched Description: … 7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and
Aganepag isopropyl is under investigation in clinical trial NCT01110499 (Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension).
Investigational
Matched Description: … Aganepag isopropyl is under investigation in clinical trial NCT01110499 (Safety and Efficacy of AGN-210961 …
Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (Cuti) or Acute Pyelonephritis (AP)).
Investigational
Matched Description: … Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety …
Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.
Investigational
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
Investigational
Matched Description: … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel …
An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).
Experimental
Matched Description: … configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and
Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.
Withdrawn
Matched Description: … Safrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against …
ABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy).
Investigational
Matched Description: … ABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy …
FB-101 is a c-Abl inhibitor. Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).
Experimental
Investigational
Matched Description: … , it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and
Experimental
Experimental
Displaying drugs 14551 - 14575 of 15275 in total